Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial

Glenn R. Cunningham, Susan S. Ellenberg, Shalender Bhasin, Alvin M. Matsumoto, J. Kellogg Parsons, Peter Preston, Jane A. Cauley, Thomas M. Gill, Ronald S. Swerdloff, Christina Wang, Kristine E. Ensrud, Cora E. Lewis, Marco Pahor, Jill P. Crandall, Mark E. Molitch, Denise Cifelli, Shehzad Basaria, Susan J. Diem, Alisa J. Stephens-Shields, Xiaoling HouPeter J. Snyder

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

CONTEXT: Prostate-specific antigen (PSA) changes during testosterone treatment of older hypogonadal men have not been rigorously evaluated. DESIGN: Double-blinded, placebo-controlled trial. SETTING: Twelve US academic medical centers. PARTICIPANTS: Seven hundred ninety hypogonadal men ≥65 years of age with average testosterone levels ≤275 ng/dL. Men at high risk for prostate cancer were excluded. INTERVENTIONS: Testosterone or placebo gel for 12 months. MAIN OUTCOMES: Percentile changes in PSA during testosterone treatment of 12 months. RESULTS: Testosterone treatment that increased testosterone levels from 232 ± 63 ng/dL to midnormal was associated with a small but substantially greater increase (P < 0.001) in PSA levels than placebo treatment. Serum PSA levels increased from 1.14 ± 0.86 ng/mL (mean ± SD) at baseline by 0.47 ± 1.1 ng/mL at 12 months in the testosterone group and from 1.25 ± 0.86 ng/mL by 0.06 ± 0.72 ng/mL in the placebo group. Five percent of men treated with testosterone had an increase ≥1.7 ng/mL and 2.5% of men had an increase of ≥3.4 ng/mL. A confirmed absolute PSA >4.0 ng/mL at 12 months was observed in 1.9% of men in the testosterone group and 0.3% in the placebo group. Four men were diagnosed with prostate cancer; two were Gleason 8. CONCLUSIONS: When hypogonadal older men with normal baseline PSA are treated with testosterone, 5% had an increase in PSA ≥1.7 ng/mL, and 2.5% had an increase ≥3.4 ng/mL.

Original languageEnglish (US)
Pages (from-to)6238-6246
Number of pages9
JournalThe Journal of clinical endocrinology and metabolism
Volume104
Issue number12
DOIs
StatePublished - Dec 1 2019

Fingerprint

Prostate-Specific Antigen
Testosterone
Placebos
Therapeutics
Prostatic Neoplasms
Gels

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Cunningham, G. R., Ellenberg, S. S., Bhasin, S., Matsumoto, A. M., Parsons, J. K., Preston, P., ... Snyder, P. J. (2019). Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial. The Journal of clinical endocrinology and metabolism, 104(12), 6238-6246. https://doi.org/10.1210/jc.2019-00806

Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men : Data from a Controlled Trial. / Cunningham, Glenn R.; Ellenberg, Susan S.; Bhasin, Shalender; Matsumoto, Alvin M.; Parsons, J. Kellogg; Preston, Peter; Cauley, Jane A.; Gill, Thomas M.; Swerdloff, Ronald S.; Wang, Christina; Ensrud, Kristine E.; Lewis, Cora E.; Pahor, Marco; Crandall, Jill P.; Molitch, Mark E.; Cifelli, Denise; Basaria, Shehzad; Diem, Susan J.; Stephens-Shields, Alisa J.; Hou, Xiaoling; Snyder, Peter J.

In: The Journal of clinical endocrinology and metabolism, Vol. 104, No. 12, 01.12.2019, p. 6238-6246.

Research output: Contribution to journalArticle

Cunningham, GR, Ellenberg, SS, Bhasin, S, Matsumoto, AM, Parsons, JK, Preston, P, Cauley, JA, Gill, TM, Swerdloff, RS, Wang, C, Ensrud, KE, Lewis, CE, Pahor, M, Crandall, JP, Molitch, ME, Cifelli, D, Basaria, S, Diem, SJ, Stephens-Shields, AJ, Hou, X & Snyder, PJ 2019, 'Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial', The Journal of clinical endocrinology and metabolism, vol. 104, no. 12, pp. 6238-6246. https://doi.org/10.1210/jc.2019-00806
Cunningham, Glenn R. ; Ellenberg, Susan S. ; Bhasin, Shalender ; Matsumoto, Alvin M. ; Parsons, J. Kellogg ; Preston, Peter ; Cauley, Jane A. ; Gill, Thomas M. ; Swerdloff, Ronald S. ; Wang, Christina ; Ensrud, Kristine E. ; Lewis, Cora E. ; Pahor, Marco ; Crandall, Jill P. ; Molitch, Mark E. ; Cifelli, Denise ; Basaria, Shehzad ; Diem, Susan J. ; Stephens-Shields, Alisa J. ; Hou, Xiaoling ; Snyder, Peter J. / Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men : Data from a Controlled Trial. In: The Journal of clinical endocrinology and metabolism. 2019 ; Vol. 104, No. 12. pp. 6238-6246.
@article{be7210da91384268a85c4a743ec475d7,
title = "Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial",
abstract = "CONTEXT: Prostate-specific antigen (PSA) changes during testosterone treatment of older hypogonadal men have not been rigorously evaluated. DESIGN: Double-blinded, placebo-controlled trial. SETTING: Twelve US academic medical centers. PARTICIPANTS: Seven hundred ninety hypogonadal men ≥65 years of age with average testosterone levels ≤275 ng/dL. Men at high risk for prostate cancer were excluded. INTERVENTIONS: Testosterone or placebo gel for 12 months. MAIN OUTCOMES: Percentile changes in PSA during testosterone treatment of 12 months. RESULTS: Testosterone treatment that increased testosterone levels from 232 ± 63 ng/dL to midnormal was associated with a small but substantially greater increase (P < 0.001) in PSA levels than placebo treatment. Serum PSA levels increased from 1.14 ± 0.86 ng/mL (mean ± SD) at baseline by 0.47 ± 1.1 ng/mL at 12 months in the testosterone group and from 1.25 ± 0.86 ng/mL by 0.06 ± 0.72 ng/mL in the placebo group. Five percent of men treated with testosterone had an increase ≥1.7 ng/mL and 2.5{\%} of men had an increase of ≥3.4 ng/mL. A confirmed absolute PSA >4.0 ng/mL at 12 months was observed in 1.9{\%} of men in the testosterone group and 0.3{\%} in the placebo group. Four men were diagnosed with prostate cancer; two were Gleason 8. CONCLUSIONS: When hypogonadal older men with normal baseline PSA are treated with testosterone, 5{\%} had an increase in PSA ≥1.7 ng/mL, and 2.5{\%} had an increase ≥3.4 ng/mL.",
author = "Cunningham, {Glenn R.} and Ellenberg, {Susan S.} and Shalender Bhasin and Matsumoto, {Alvin M.} and Parsons, {J. Kellogg} and Peter Preston and Cauley, {Jane A.} and Gill, {Thomas M.} and Swerdloff, {Ronald S.} and Christina Wang and Ensrud, {Kristine E.} and Lewis, {Cora E.} and Marco Pahor and Crandall, {Jill P.} and Molitch, {Mark E.} and Denise Cifelli and Shehzad Basaria and Diem, {Susan J.} and Stephens-Shields, {Alisa J.} and Xiaoling Hou and Snyder, {Peter J.}",
year = "2019",
month = "12",
day = "1",
doi = "10.1210/jc.2019-00806",
language = "English (US)",
volume = "104",
pages = "6238--6246",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "12",

}

TY - JOUR

T1 - Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men

T2 - Data from a Controlled Trial

AU - Cunningham, Glenn R.

AU - Ellenberg, Susan S.

AU - Bhasin, Shalender

AU - Matsumoto, Alvin M.

AU - Parsons, J. Kellogg

AU - Preston, Peter

AU - Cauley, Jane A.

AU - Gill, Thomas M.

AU - Swerdloff, Ronald S.

AU - Wang, Christina

AU - Ensrud, Kristine E.

AU - Lewis, Cora E.

AU - Pahor, Marco

AU - Crandall, Jill P.

AU - Molitch, Mark E.

AU - Cifelli, Denise

AU - Basaria, Shehzad

AU - Diem, Susan J.

AU - Stephens-Shields, Alisa J.

AU - Hou, Xiaoling

AU - Snyder, Peter J.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - CONTEXT: Prostate-specific antigen (PSA) changes during testosterone treatment of older hypogonadal men have not been rigorously evaluated. DESIGN: Double-blinded, placebo-controlled trial. SETTING: Twelve US academic medical centers. PARTICIPANTS: Seven hundred ninety hypogonadal men ≥65 years of age with average testosterone levels ≤275 ng/dL. Men at high risk for prostate cancer were excluded. INTERVENTIONS: Testosterone or placebo gel for 12 months. MAIN OUTCOMES: Percentile changes in PSA during testosterone treatment of 12 months. RESULTS: Testosterone treatment that increased testosterone levels from 232 ± 63 ng/dL to midnormal was associated with a small but substantially greater increase (P < 0.001) in PSA levels than placebo treatment. Serum PSA levels increased from 1.14 ± 0.86 ng/mL (mean ± SD) at baseline by 0.47 ± 1.1 ng/mL at 12 months in the testosterone group and from 1.25 ± 0.86 ng/mL by 0.06 ± 0.72 ng/mL in the placebo group. Five percent of men treated with testosterone had an increase ≥1.7 ng/mL and 2.5% of men had an increase of ≥3.4 ng/mL. A confirmed absolute PSA >4.0 ng/mL at 12 months was observed in 1.9% of men in the testosterone group and 0.3% in the placebo group. Four men were diagnosed with prostate cancer; two were Gleason 8. CONCLUSIONS: When hypogonadal older men with normal baseline PSA are treated with testosterone, 5% had an increase in PSA ≥1.7 ng/mL, and 2.5% had an increase ≥3.4 ng/mL.

AB - CONTEXT: Prostate-specific antigen (PSA) changes during testosterone treatment of older hypogonadal men have not been rigorously evaluated. DESIGN: Double-blinded, placebo-controlled trial. SETTING: Twelve US academic medical centers. PARTICIPANTS: Seven hundred ninety hypogonadal men ≥65 years of age with average testosterone levels ≤275 ng/dL. Men at high risk for prostate cancer were excluded. INTERVENTIONS: Testosterone or placebo gel for 12 months. MAIN OUTCOMES: Percentile changes in PSA during testosterone treatment of 12 months. RESULTS: Testosterone treatment that increased testosterone levels from 232 ± 63 ng/dL to midnormal was associated with a small but substantially greater increase (P < 0.001) in PSA levels than placebo treatment. Serum PSA levels increased from 1.14 ± 0.86 ng/mL (mean ± SD) at baseline by 0.47 ± 1.1 ng/mL at 12 months in the testosterone group and from 1.25 ± 0.86 ng/mL by 0.06 ± 0.72 ng/mL in the placebo group. Five percent of men treated with testosterone had an increase ≥1.7 ng/mL and 2.5% of men had an increase of ≥3.4 ng/mL. A confirmed absolute PSA >4.0 ng/mL at 12 months was observed in 1.9% of men in the testosterone group and 0.3% in the placebo group. Four men were diagnosed with prostate cancer; two were Gleason 8. CONCLUSIONS: When hypogonadal older men with normal baseline PSA are treated with testosterone, 5% had an increase in PSA ≥1.7 ng/mL, and 2.5% had an increase ≥3.4 ng/mL.

UR - http://www.scopus.com/inward/record.url?scp=85074377247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074377247&partnerID=8YFLogxK

U2 - 10.1210/jc.2019-00806

DO - 10.1210/jc.2019-00806

M3 - Article

C2 - 31504596

AN - SCOPUS:85074377247

VL - 104

SP - 6238

EP - 6246

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 12

ER -